Table 3.

Adverse events of TPN as first line treatment for ESCC (N = 56)

Adverse events	Grade 1 (%)	Grade 2 (%)	Grade 3 (%)	Grade 4 (%)
Neutropenia	9 (16.1)	5 (8.9)	19 (33.9)	7 (12.5)
Leukopenia	12 (21.4)	15 (26.8)	12 (21.4)	2 (3.6)
Thrombopenia	4 (7.1)	2 (3.6)	0	0
Anaemia	18 (32.1)	2 (3.6)	1 (1.8)	0
Febrile neutropenia	1 (1.8)	0	2 (3.6)	0
Fatigue	31 (55.4)	7 (12.5)	1 (1.8)	0
Anorexia	20 (35.7)	4 (7.1)	1 (1.8)	0
Stomatitis	6 (10.7)	2 (3.6)	0	0
Nausea	24 (42.9)	3 (5.4)	0	0
Vomiting	20 (35.7)	8 (14.3)	3 (5.4)	0
Dry Skin	9 (16.1)	0	0	0
Constipation	6 (10.7)	1 (1.8)	0	0
Alopecia	17 (30.4)	27 (48.2)	0	0
Skin pruritus	15 (26.8)	0	0	0
Skin pigmentation	3 (5.4)	0	0	0
Arthralgia	24 (42.9)	3 (5.4)	1 (1.8)	0
Neuropathy	15 (26.8)	3 (5.4)	2 (3.6)	0
Liver function change	5 (8.9)	2 (3.6)	0	0
Hematuria	1 (1.8)	0	0	0
Proteinuria	1 (1.8)	0	0	0

ESCC, esophageal squamous cell carcinoma; TPN, nimotuzumab with paclitaxel and cisplatin.